Abstract:Background: Cytokine fusion protein that modulates the immune response holds great potential for cancer immunotherapy. IL-2 is an effective treatment against advanced cancers. However, the therapeutic efficacy of IL-2 is limited by severe systemic toxicity. Several mutants recombinant IL-2 can increase antitumor activity and minimize systemic toxicity. Melittin is an attractive anticancer candidate because of its wide-spectrum lytic properties. We previously generated a bifunctional fusion protein melittin-MIL-2, composed of melittin and a mutant IL-2. The melittin-MIL-2 inhibited the growth of human ovarian cancer SKOV3 cells in vitro and in vivo tumor growth. However, whether this antitumor effect could also be used in cancer immunotherapy was unknown. To assess its cancer immunotherapy potential, we further investigated its more effective antitumor immune response and antitumor effect against cancers of different tissue origins in vitro and in vivo. Methods: The specific IL-2 activity of the melittin-MIL-2 fusion protein was tested on the cytokine growth dependent cell line CTLL-2. The cytolytic activity was detected by standard 4-h (51)Cr-release assays. PBMC stimulation in response to the melittin-MIL-2 was determined by IFN-γ release assay. We observed the cancer cell proliferation of different tissue origins by MTT assay. The ability of melittin-MIL-2 to inhibit tumor growth in vivo was evaluated by using human liver (SMMC-7721 cancer cells), lung (A549 cancer cells) and ovarian (SKOV3 cancer cells) cancer xenograft models. To assess the immunity within the tumor microenvironment, the level of some cytokines including IFN-γ, TNF-α, IL-12 and IL-4 was analyzed by ELISA. We injected the MDA-MB-231 cells and the melittin-MIL-2 into mice, and the anti-metastatic effect was examined by counting nodules in the lung. Results: The melittin-MIL-2 was more effective in inducing T cell and NK-cell cytotoxicity. The fusion protein significantly increased IFN-γ production in PBMCs. In vitro, the melittin-MIL-2 mediated immune cells killing or directly killed the cancer cell lines of different tissue origins. In vivo, the fusion protein exhibited stronger inhibition on the growth of transplanted human tumors compared to rIL-2. The melittin-MIL-2 treatment promoted the IFN-γ secretion in tumor tissues and decreased the immunosuppressive cells in vivo. Furthermore, the fusion protein reduced lung metastasis of breast cancer. Conclusions: This study provides the evidence that the melittin-MIL-2 can produce stronger immune stimulation and antitumor effects, and the fusion protein is a potent candidate for cancer immunotherapy.

Construction and characterization of an anti-asialoglycoprotein receptor single-chain variable-fragment-targeted melittin.

Targeting Tumor Cells by Natural Anti-Carbohydrate Antibodies Using Rhamnose-Functionalized Liposomes.

Construction, expression, and characterization of an anti-tumor immunotoxin containing the human anti-c-Met single-chain antibody and PE38KDEL

Construction of Membrane-lytic Immunotoxin by Melittin and Epidermal Growth Factor

Design of pH-responsive antimicrobial peptide melittin analog-camptothecin conjugates for tumor therapy

Preliminary Study on the Leukemia Targeting by a CD19 Antibody Conjugated with Saline Extracts from Mylabris Phalerata Pallas.

Construction and Expression of a Humanoral Recombinant Immunotoxin Against Hepatocellular Carcinoma and Its Killing Effect on HCC Cell Line

Turning Toxicants into Safe Therapeutic Drugs: Cytolytic Peptide−Photosensitizer Assemblies for Optimized In Vivo Delivery of Melittin

Successful construction and massive expression of a novel Anti-CD19 human-mouse chimeric antibody Hm2E8b.

Inhibitory effect of recombinant adenovirus carrying melittin gene on hepatocellular carcinoma

Targeting of Hepatoma Cell and Suppression of Tumor Growth by A Novel 12mer Peptide Fused to Superantigen Tsst-1

Construction, Expression, and Characterization of a Recombinant Immunotoxin Targeting EpCAM.

Zwitterionic Peptide Pendant As a Homing Agent to Achieve Lymphatic Targeting Antigen-Specific Immunotherapy of Allergenic Protein

Selection and Characterization of Human Anti-MAGE-A1 Scfv and Immunotoxin

Genetically engineered nano-melittin vesicles for multimodal synergetic cancer therapy

A cell surface-binding antibody atlas nominates a MUC18-directed antibody-drug conjugate for targeting melanoma

Construction and Preclinical Evaluation of 211at Labeled Anti-mesothelin Antibodies As Potential Targeted Alpha Therapy Drugs

Construction and Evaluation of GPC3-Targeted Immunotoxins As a Novel Therapeutic Modality for Hepatocellular Carcinoma

Melittin-encapsulating Peptide Hydrogels for Enhanced Delivery of Impermeable Anticancer Peptides.

Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy

Stable Loading and Delivery of Melittin with Lipid-Coated Polymeric Nanoparticles for Effective Tumor Therapy with Negligible Systemic Toxicity